Loading...

PE anti-mouse CD69 Antibody PE anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PE_083106
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
  • H1dot2F3_PE_083106
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104508 200 µg NOK2418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104507 50 µg NOK1007
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  3. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  4. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  5. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  6. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  7. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  8. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  9. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  10. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  11. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  12. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  13. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  14. Liu M, et al. 2022. Cells. 11: . PubMed
  15. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  16. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  17. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  18. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  19. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  20. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  21. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  22. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  23. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  24. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  27. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  28. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  29. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  30. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  31. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  32. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  33. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  34. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  35. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  36. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  37. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  38. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  39. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  40. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  41. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  42. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  43. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  44. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  45. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  46. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  47. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  48. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  49. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  50. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  51. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  52. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  53. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  54. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  55. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  56. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  57. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  58. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  59. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  60. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  61. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  62. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  63. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  64. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  65. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  67. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  68. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  69. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  70. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  71. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  72. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  73. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  74. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  75. Lopes N, et al. 2022. Elife. 11:. PubMed
  76. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  77. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  78. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  79. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  80. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  81. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  82. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  83. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  84. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  85. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  86. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  87. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  88. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  89. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  90. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  91. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  92. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  93. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  94. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  95. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  96. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  97. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  98. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  99. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  100. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  101. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  102. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  103. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  104. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  105. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  106. Liu M, et al. 2022. Cells. 11: . PubMed
  107. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  108. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  109. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  110. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  111. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  112. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  113. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  114. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  115. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  116. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  117. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  118. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  119. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  120. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  121. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  122. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  123. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  124. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  125. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  126. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  127. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  128. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  129. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  130. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  131. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  132. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  133. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  134. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  135. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  136. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  137. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  138. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  139. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  140. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  141. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  142. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  143. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  144. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  145. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  146. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  147. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  148. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  149. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  150. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  151. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  152. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  153. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  154. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  155. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  156. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  157. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  158. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  159. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  160. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  161. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  162. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  163. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  164. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  165. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  166. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  167. Lopes N, et al. 2022. Elife. 11:. PubMed
  168. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  169. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  170. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  171. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  172. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  173. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  174. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  175. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  176. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  177. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  178. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  179. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  180. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  181. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  182. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  183. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  184. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_313111 (BioLegend Cat. No. 104508)
AB_313110 (BioLegend Cat. No. 104507)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 4    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PE_083106
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
  • H1dot2F3_PE_083106
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104508 200 µg NOK2418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104507 50 µg NOK1007
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  3. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  4. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  5. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  6. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  7. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  8. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  9. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  10. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  11. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  12. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  13. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  14. Liu M, et al. 2022. Cells. 11: . PubMed
  15. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  16. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  17. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  18. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  19. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  20. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  21. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  22. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  23. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  24. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  27. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  28. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  29. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  30. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  31. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  32. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  33. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  34. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  35. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  36. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  37. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  38. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  39. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  40. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  41. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  42. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  43. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  44. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  45. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  46. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  47. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  48. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  49. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  50. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  51. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  52. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  53. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  54. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  55. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  56. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  57. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  58. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  59. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  60. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  61. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  62. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  63. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  64. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  65. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  67. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  68. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  69. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  70. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  71. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  72. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  73. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  74. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  75. Lopes N, et al. 2022. Elife. 11:. PubMed
  76. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  77. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  78. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  79. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  80. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  81. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  82. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  83. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  84. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  85. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  86. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  87. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  88. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  89. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  90. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  91. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  92. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  93. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  94. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  95. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  96. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  97. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  98. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  99. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  100. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  101. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  102. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  103. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  104. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  105. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  106. Liu M, et al. 2022. Cells. 11: . PubMed
  107. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  108. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  109. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  110. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  111. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  112. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  113. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  114. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  115. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  116. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  117. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  118. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  119. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  120. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  121. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  122. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  123. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  124. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  125. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  126. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  127. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  128. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  129. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  130. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  131. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  132. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  133. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  134. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  135. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  136. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  137. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  138. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  139. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  140. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  141. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  142. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  143. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  144. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  145. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  146. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  147. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  148. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  149. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  150. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  151. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  152. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  153. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  154. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  155. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  156. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  157. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  158. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  159. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  160. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  161. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  162. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  163. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  164. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  165. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  166. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  167. Lopes N, et al. 2022. Elife. 11:. PubMed
  168. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  169. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  170. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  171. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  172. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  173. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  174. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  175. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  176. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  177. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  178. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  179. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  180. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  181. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  182. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  183. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  184. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_313111 (BioLegend Cat. No. 104508)
AB_313110 (BioLegend Cat. No. 104507)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 4    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account